The past year has been another one of change. Those in the industry know that R&D innovation is driving more activity in the sector than ever before. As biosimilars gradually increase their place on the market and payers worldwide demand price restraints, we've seen industry renewal through the development and launch of a number of new therapy modes that truly offer tremendous value to patients and society, from gene and cell therapies to continuing advances in immuno-oncology. Meanwhile, data and artificial intelligence tools are helping to drive transformation across the industry's activities. A glance at the winners of the 2018 Scrip Awards show that the future is bright for biopharma.
The Scrip Awards categories range from those that reward the broader achievements of companies, to those for innovation in deal...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
